NCT01527305 - An Open-Label, Prospective, Non-Comparative Study to Evaluate the Efficacy and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia

CSR Summary
NCT01527305
Primary Citation Not Available
Data Specification Not Available

Trial Information

Generic NamePaliperidone palmitateProduct NameINVEGA SUSTENNA®Therapeutic AreaBehaviors and Mental DisordersEnrollment212% Female49%% WhiteN/A

Product ClassAtypical AntipsychoticsSponsor Protocol NumberR092670SCH4009Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)37.1

Supporting Documentation

Collected Datasets Available
Protocol with Amendments Available
Statistical Analysis Plan Available
Clinical Study Report Available

Approved Data Requests Associated with this Trial

2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
2021-4667 : Estimation of Geographic and Demographic Variabilities Associated with Schizophrenia Age of Onset and Duration of Untreated Psychosis
2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment

You are not logged in.

Trial Information

Supporting Documentation

Approved Data Requests Associated with this Trial